| ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company | 06/17 14:05 | benzinga.com |
| Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise | 06/03 12:00 | newsfilecorp.com |
| Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications | 05/30 16:01 | globenewswire.com |
| Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications | 05/30 16:01 | newsfilecorp.com |
| Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript | 05/15 10:07 | seekingalpha.com |
| Adaptimmune Reports Q1 2024 Financial and Business Updates | 05/15 07:30 | newsfilecorp.com |
| Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital | 05/15 07:00 | newsfilecorp.com |
| Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 | 05/01 12:00 | newsfilecorp.com |
| Adaptimmune: Huge Opportunity Amid Their Setback With Genentech | 04/26 11:00 | seekingalpha.com |
| Adaptimmune (ADAP) Down on End of Collaboration With Roche | 04/15 15:16 | zacks.com |